Modi S - Search Results

1

The heat shock protein 90 chaperone complex: an evolving therapeutic target.

Barginear MF, Van Poznak C, Rosen N, Modi S, Hudis CA, Budman DR. Barginear MF, et al. Among authors: modi s. Curr Cancer Drug Targets. 2008 Sep;8(6):522-32. doi: 10.2174/156800908785699379. Curr Cancer Drug Targets. 2008. PMID: 18781898 Review.

2

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. Modi S, et al. Breast Cancer Res Treat. 2005 Mar;90(2):157-63. doi: 10.1007/s10549-004-3974-0. Breast Cancer Res Treat. 2005. PMID: 15803362 Clinical Trial.

3

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. Modi S, et al. Clin Breast Cancer. 2005 Apr;6(1):55-60. doi: 10.3816/CBC.2005.n.009. Clin Breast Cancer. 2005. PMID: 15899073 Clinical Trial.

4

Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.

Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Fornier MN, et al. Among authors: modi s. Cancer. 2005 Oct 15;104(8):1575-9. doi: 10.1002/cncr.21385. Cancer. 2005. PMID: 16134178 Free article.

5

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.

Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Modi S, et al. Cancer Invest. 2005;23(6):483-7. doi: 10.1080/07357900500201301. Cancer Invest. 2005. PMID: 16203655

6

A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.

Modi S, D'Andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP, Hudis C, Seidman AD. Modi S, et al. Clin Breast Cancer. 2006 Aug;7(3):270-7. doi: 10.3816/CBC.2006.n.040. Clin Breast Cancer. 2006. PMID: 16942645 Clinical Trial.

7

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Modi S, et al. J Clin Oncol. 2007 Dec 1;25(34):5410-7. doi: 10.1200/JCO.2007.11.7960. J Clin Oncol. 2007. PMID: 18048823 Clinical Trial.

8

Preoperative chemotherapy for breast cancer: miracle or mirage?

Hudis C, Modi S. Hudis C, et al. Among authors: modi s. JAMA. 2007 Dec 12;298(22):2665-7. doi: 10.1001/jama.298.22.2665. JAMA. 2007. PMID: 18073362 No abstract available.

9

Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.

Morris PG, Poznak CV, Modi S, Mak AF, Patil S, Larson S, Hudis CA, Divgi C, Grewal RK. Morris PG, et al. Among authors: modi s. Clin Breast Cancer. 2010 Feb;10(1):33-9. doi: 10.3816/CBC.2010.n.004. Clin Breast Cancer. 2010. PMID: 20133256 Clinical Trial.

10

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.

Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA. Fornier MN, et al. Among authors: modi s. Ann Oncol. 2011 Dec;22(12):2575-2581. doi: 10.1093/annonc/mdr018. Epub 2011 Mar 15. Ann Oncol. 2011. PMID: 21406471 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

718 results

Search Page

Filters